Independent Drug Value Assessment Act
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 17, 2022
Referred to the Subcommittee on Health.
Nov 16, 2022
Referred to the House Committee on Energy and Commerce.
Nov 16, 2022
Introduced in House
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Plain-English summary
Independent Drug Value Assessment Act
This bill requires the Office of the Assistant Secretary for Planning and Evaluation to contract with outside entities to conduct independent value assessments of approved drugs (i.e., economic analysis of the benefits to patients and the health care system).
What's happening now
Referred to the Subcommittee on Health.
Bill text
1 version
- Introduced in House Formatted Text PDF Formatted XML
Committees of jurisdiction
2
Cosponsors
1
Cite this page
U.S. Congress. (2026). H.R. 9321: Independent Drug Value Assessment Act. 117th Congress. Open America. https://openamerica.io/bill/117-HR-9321/
"H.R. 9321: Independent Drug Value Assessment Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-9321/.
H.R. 9321, 117th Cong. (2026), https://openamerica.io/bill/117-HR-9321/.
[H.R. 9321: Independent Drug Value Assessment Act](https://openamerica.io/bill/117-HR-9321/)